Search results
- Regulatory news (469) Apply Regulatory news filter
- Press releases (177) Apply Press releases filter
- Basic page (45) Apply Basic page filter
- Pipeline (19) Apply Pipeline filter
- Corporate presentations (18) Apply Corporate presentations filter
- Shareholder meeting (17) Apply Shareholder meeting filter
- Team member (17) Apply Team member filter
- Videos (14) Apply Videos filter
- Financial reports (10) Apply Financial reports filter
- Analyst (9) Apply Analyst filter
- Event (8) Apply Event filter
- Webcasts and audio (7) Apply Webcasts and audio filter
- Investor contact (6) Apply Investor contact filter
- Research (3) Apply Research filter
LentiVector platform
The LentiVector® platform is the only commercially approved lentiviral-based gene delivery system.
The TRiP System
The TRiP SystemTM maximises viral vector production output and standardises downstream process
Packaging and producer cell lines
Oxford BioMedica has developed packaging and inducible producer cell lines that enable a simplified and scalable manufacturing process whil
Analytical methods
Oxford BioMedica has developed and optimised all the analytics necessary to support product commercialisation.
Vectors with safety features
Oxford BioMedica’s LentiVector® platform is designed to give the highest safety and efficacy.
Automation and robotics
The LentiVector® platform integrates automated systems enabling scalable and cost-effective manufacture of lentiviral vectors.
200L serum-free suspension cell culture
Oxford BioMedica established serum-free suspension production processes to enhance vector output.
Data analytics and artificial intelligence
Oxford BioMedica is introducing Data Analytics and Artificial Intelligence in its systems to improve productivity and product quality